ETF Resumé

PBETicker Symbol

Dynamic Biotech & Genome PowersharesFund


  • Healthcare ETFs Are Latest Victim to Trump

    01-11-2017 02:21 PM by Max Chen

    Healthcare stocks, especially the biotech segment, and related exchange traded funds plunged Wednesday after President-elect Donald Trump singled out the rising drug prices at a press conference. The healthcare sector was the worst performing area of the equities market on Wed...

    Read more

  • M&A Activity, Passing Drug Trials Help Biotech ETFs Rebound

    09-12-2016 02:47 PM by Max Chen

    A large acquisition and favorable results from a drug trial helped biotechnology and pharmaceutical sector-related exchange traded funds rally on Monday. Among the best performing ETFs of Monday, the PowerShares Dynamic Biotech & Genome (NYSEArca:PBE) jumped 3.0%, ALPS Med...

    Read more

  • Pfizer Acquires Medivation, Renews Biotech M&A Bets

    08-22-2016 02:20 PM by Max Chen

    Pfizer (NYSE: PFE) announced a $14 billion deal to acquire cancer drug developer Medivation (NasdaqGS: MDVN), propelling the broader biotechnology exchange traded funds higher on speculation of more deals in the sector. Biopharmaceutical giant Pfizer will pay Medivation shareh...

    Read more

  • 10 Best & Worst ETF Performers of the Day (May 11)

    05-11-2016 05:04 PM by Brenton Garen

    Welcome to the 10 Best & Worst ETF Performers of the Day for Wednesday, May 11, 2016. 10 Best ETF Performers: Sym Name Last Percent Volume UGA US Gasoline 27.57 +5.55% 93,722 SGG DJ-UBS Sugar TR Sub-Idx ETN Ipat...

    Read more

  • Hit The Lab With These 17 Biotech ETFs

    05-02-2016 12:49 PM by Tom Lydon

    The time to buy, regardless of sector, is usually when a particular group falls out of favor, not when it has been bid higher by scores of investors. Some investors view that as the case with the broader healthcare group and biotechnology in particular. Multiple factors, inclu...

    Read more

  • ETF Chart of the Day: Hot Biotechnology Sector

    07-30-2015 12:47 PM by Paul Weisbruch, Street One Financial

    This week we have seen decent sized inflows in the largest Biotech Equity based ETP in the U.S. listed landscape, IBB (iShares NASDAQ Biotechnology, Expense Ratio 0.48%), to the tune of about $400 million. Net year to date the fund has reeled in north of $1.2 billion now, push...

    Read more

  • Biotech Hedge Funds are hot, but Biotech ETFs are Hotter

    05-29-2015 02:05 PM by Todd Shriber

    It is no secret that investors love biotechnology stocks and the related exchange traded funds. That love extends to hedge funds, some of which are dedicated healthcare and biotech funds. Hedge funds that focus exclusively on biotech or invest in the space as part of a diversi...

    Read more

  • These ETFs Will Like the Dyax News

    04-01-2015 07:45 AM by Todd Shriber

    Shares of Dyax Corp. (NasdaqGS: DYAX) surged nearly 50% during Tuesdays after-hours session after the Massachusetts-based company said an early stage trial of its treatment for hereditary angioedema proved safe for use and effective in reducing extreme swelling attacks. Dyax a...

    Read more

  • ETFs for the Next Biotech Takeover Targets

    03-10-2015 11:00 AM by Todd Shriber

    On the heels of last weeks news that AbbVie (NYSE: ABBV) will acquire cancer treatments maker Pharmacyclics (NasdaqGS: PCYC) for $21 billion, speculation is abound regarding the next potential takeover targets in the biotechnology industry. The biotech industry and the relevan...

    Read more

  • Biotech ETFs Sholud Like AbbVie's bid for Pharmacyclics

    03-05-2015 07:30 AM by Todd Shriber

    Shares of Pharmacyclics (NasdaqGS: PCYC), a maker of cancer treatments, rose more than 2% during Wednesdays after-hours session following a 6.3% surge on almost two and a half times the average voile during tradition trading hours on reports Dow component Johnson & Johnson (N...

    Read more

  • Tis the Season for Biotech ETFs

    01-05-2015 08:00 AM by Todd Shriber

    Over the last several years, there has rarely been a bad time to own biotechnology exchange traded funds. That much is confirmed by the presence of multiple biotech ETFs on the annual lists of the top 10 sector funds. In 2014, each of the five major biotech ETFs ranked among t...

    Read more

  • The Dominance of Health Care ETFs in One Chart

    11-20-2014 09:30 AM by Todd Shriber

    Stellar performances by health care stocks and exchange traded funds this year have been well-document and plenty of investors know that the Health Care Select Sector SPDR (NYSEArca: XLV) is the best of the nine sector SPDR ETFs to this point in the year. Up 24.7% year-to-date...

    Read more

  • Biotech ETFs Prescribe New ETFs

    10-23-2014 11:49 AM by Todd Shriber

    U.S. stocks appear headed for a fifth consecutive day of gains. While that is good news, the S&P 500s recent winning streak serves as a reminder regarding why October is, historically, the most volatile month of the year. Despite that volatility, biotechnology exchange tra...

    Read more

  • Biotech ETFs Arent Waving the White FlagYet

    10-15-2014 08:00 AM by Tom Lydon

    One of this years sharpest pullbacks in equities was, some market observers would say, attributable to the late first-quarter/early second-quarter retrenchment in biotechnology stocks and the corresponding exchange traded funds. So severe was the aforementioned selloff in biot...

    Read more

  • Biotech ETFs Look to Build on Hot August Returns

    09-03-2014 11:00 AM by Tom Lydon

    It was a frequent event in the month of August. Throughout the month, daily checks of exchange traded funds making new all-time highs turned up plenty of health care funds. Much to the chagrin of the biotechnology bears that growled so loud late in the first quarter and early ...

    Read more

  • InterMune Acquisition Could Ignite These Biotech ETFs

    08-25-2014 09:00 AM by Tom Lydon

    Monday could prove to be another day of biotechnology merger mania for the exchange traded funds holding the sectors stocks after Swiss pharmaceuticals giant Roche announced Sunday it will acquire InterMune (NasdaqGS: ITMN) for $8.3 billion in cash. Roche will pay $74 per shar...

    Read more

  • So Much for That Biotech ETF Bubble

    08-20-2014 12:28 PM by Todd Shriber

    It seems like only yesterday that there was a cacophony of criticism and doubt from naysayers regarding biotechnology stock and exchange traded funds. In reality, yesterday was the first quarter when the usually pricey biotech sector soared to valuations that were double its a...

    Read more

  • Most Searched ETFs: Surging Sectors

    06-14-2014 08:00 AM by Todd Shriber

    U.S. stocks managed to closer higher Friday, but in a case of June gloom, the S&P 500 snapped a multi-week winning streak. Escalating tensions at the hands of a militant faction of al-Qaeda in Iraq weighed on stocks, but sent oil prices soaring. On that note, it is surpris...

    Read more

  • The Biotech ETF Rally No One is Talking About

    06-09-2014 01:25 PM by Todd Shriber

    Perhaps it is just the way the media operate, an unfortunate byproduct of people paying ample attention to negative news or both, but there is a rally going on in biotechnology stocks and exchange traded funds that is receiving scant attention. From its March 4th peak to its A...

    Read more

  • Why These Two Biotech ETFs Are Soaring Monday

    06-09-2014 12:09 PM by Tom Lydon

    The PowerShares Dynamic Biotechnology & Genome Portfolio (NYSEArca: PBE) and the SPDR S&P Biotech ETF (NYSEArca: XBI) are up 8.4% and 6.8%, respectively, Monday, making the duo the days two best non-leveraged ETFs. PBE and XBI are soaring because the two ETFs feature t...

    Read more

  • More Upside Possible for Biotech ETF

    05-06-2014 12:46 PM by Todd Shriber

    From its Feb. 25 to its April 14 lows, the iShares Nasdaq Biotechnology ETF (NasdaqGM: IBB) tumbled 21.2%. That fits the definition of a bear market and IBBs decline, along those of the other biotech ETFs, received ample attention due in large part to talk that the biotech sec...

    Read more

  • Biotech Bumble: ETFs Fall to 2014 Lows

    04-10-2014 02:16 PM by Todd Shriber

    More bad price action out of the biotechnology sector Thursday and that underscores the precarious technical conditions being faced some exchange traded funds that were beloved just several weeks ago. Here is a brief recap of just how bad biotech stocks and ETFs have been sinc...

    Read more

  • Investors Say Bye-Bye to Biotech ETFs

    04-08-2014 12:45 PM by Todd Shriber

    It has been said, and it is more often than not true, that flows data for exchange data is not a predictor of future performance, but rather a sign of investors chasing past performance. When it comes to once beloved biotechnology ETFs, it is not debatable that the groups rece...

    Read more

  • Big Biotech ETF Still in UptrendFor Now

    03-26-2014 08:15 AM by Tom Lydon

    The subject has been talked to death over the past week, but that does not mean attention on the biotech sector is waning. Amid increased talk of a biotech bubble and fears of government-controlled pricing, biotech stocks and exchange traded funds have been under siege in rece...

    Read more

  • Health Care ETFs Raking in Plenty of Cash

    03-06-2014 11:54 AM by Todd Shriber

    On the surface, it would appear that equity-based exchange traded funds are struggling to keep and attract assets this year. Inflows to equity ETFs do not look poised to recapture last years magic. Even when backing out the $17.4 billion lost by the SPDR S&P 500 (NYSEArca:...

    Read more

  • Why This Biotech ETF Leads the Pack

    02-21-2014 08:15 AM by Todd Shriber

    There are five biotechnology exchange traded funds on the market today. Confirming just how strong the sub-sector has been this year three of those ETFs the First Trust NYSE Arca Biotechnology Index Fund (NYSEArca: FBT), the Market Vectors Biotech (NYSEArca: BBH) and the iShares...

    Read more

  • Health Care Heaven: Sectors ETFs Flex Their Muscles

    02-14-2014 08:00 AM by Todd Shriber

    Forty-seven exchange traded funds hit all-time highs on Thursday. In a testament to the ongoing strength of the health care sector, now the third-largest in the S&P 500, 16 of the ETFs touching all-time highs yesterday were health care funds. This is not a new phenomenon. ...

    Read more

  • The One ETF Really Benefiting From the Intercept Pharma News

    01-09-2014 01:57 PM by Todd Shriber

    No need to do a double take with the following because it is true: Shares of Intercept Pharmaceuticals (NasdaqGM: ICPT) are up $210, or a tidy 290%, after trials for the companys liver disease treatment proved successful. That is good news for the biotechnology sector, which i...

    Read more

  • Intense Duel to be 2013s Best Health Care ETF

    12-23-2013 08:00 AM by Tom Lydon

    This has been, quite simply a very, very good year in which to be long health care exchange traded funds. The Health Care Select Sector SPDR (NYSEArca: XLV) is battling with its discretionary rival to be the best of the nine SPDR ETFs for 2013 and XLV spent some time as the th...

    Read more

  • Biotech ETFs: More Tricks Than Treats in October

    10-31-2013 02:45 PM by Max Chen

    Biotech exchange traded funds, market leaders for much of this year, stumbled in October as the government shutdown had an unexpectedly debilitating affect on the high-flying sub-industry. The iShares Nasdaq Biotechnology ETF (NasdaqGS: IBB), which tracks large biotech or phar...

    Read more

  • Sell-Off in Biotech ETFs Could Be a Temporary Setback

    10-10-2013 07:30 AM by Tom Lydon

    Biotechnology exchange traded funds are on a three-day sell-off after falling short of its 52-week high Friday, but the sector can still find its footing. The he iShares Nasdaq Biotech (NasdaqGM: IBB) has declined 7.5% in the past three sessions, Market Vectors Biotech ETF (NY...

    Read more

  • 10 ETF Investments That Got the Most Bang for Your Buck

    10-08-2013 01:14 PM by Tom Lydon

    Riding out tax hikes, interest rate risk and geopolitical tensions, the broad equity markets touched historic highs this year, with alternative energy, biotech and technology stock exchange traded funds leading the pack. In the technology space, social media stocks are experie...

    Read more

  • Three ETFs to Play Up-and-Coming Health Care Companies

    09-03-2013 04:10 PM by Tom Lydon

    Rummaging through small-cap biotechnology companies, investors can pick out the next break-through drug provider, but it also leaves you exposed to potential flubs. Instead, exchange traded funds offer diversified basket to the growing sector. "The jarring pace of change, sing...

    Read more

  • Three ETFs to Play the Outperforming Biotech Sector

    08-19-2013 04:39 PM by Tom Lydon

    The biotechnology sector has been one of the best performing areas in the market this year. While investors can try to bet big, and potentially lose big, on biotech stocks, an exchange traded fund helps diversify risk with a basket of securities. "The jarring pace of change, s...

    Read more

  • Choosing the Right Biotech ETF Exposure

    04-20-2012 03:09 PM by Tom Lydon

    Coming off the hopeful drug trial tests and lucrative takeover bids, the biotech sector and related exchange traded funds that follow the industry surged this week. However, some biotechnology ETFs are doing better than the others. The large biotech firms are flush with cash a...

    Read more

  • Biotech ETFs Mixed After Gilead Subpoena

    06-13-2011 01:53 PM by Tom Lydon

    Biotechnology exchange traded funds were mixed Monday after sector bellwether Gilead Sciences (NasdaqGS: GILD) disclosed it has received a subpoena from the U.S. Department of Justice. Gilead shares were down nearly 1% but pared their earlier loss after the company late Friday...

    Read more

  • 5 Biotechnology ETFs to Play Innovation

    02-22-2011 02:00 PM by Tom Lydon

    While the broader market has picked up its pace, the biotechnology sector has not seen a similar surge in performance. Still, investors should keep in mind the various biotech exchange traded fund (ETF) plays to stay positioned for a resurgence in the sector. Currently, the bi...

    Read more

  • Why Health Care ETFs May Be In the Clear

    11-10-2010 11:00 AM by Tom Lydon

    After the Democrats lost some seats in the mid-term elections, you might be wondering whether health care revenue and exchange traded funds (ETFs) will be affected by the shift. Some don't believe there's anything to worry about for a while. First, with most corporations backi...

    Read more

  • 5 Things That Drive Biotech ETFs

    10-21-2010 03:00 PM by Tom Lydon

    The biotechnology sector is a unique one because many of the companies that compose it are not yet profitable. Here's what drives the sector and exchange traded funds (ETFs) that let you play it. Kashif Javed for Forex Trading Analysis reports that the biotech sector is driven...

    Read more

  • Biotech ETFs:The Better Way to Play

    10-11-2010 06:00 AM by Tom Lydon

    As cash-strapped biotech companies see their cash reserves dwindle, it has forced a number of companies to close up shop. The struggles faced in the sector highlights the benefits of getting exposure to it through biotech exchange traded funds (ETFs). The number of publicly-tr...

    Read more

  • Biotech ETFs: 5 Ways to Play Innovation

    08-08-2010 01:00 PM by Tom Lydon

    Biotechnology has been improving our quality of life for generations. The industry does everything from researching a cure for cancer to finding disease-resistant crops and more. While this can be a difficult sector in which to invest, there are five exchange traded funds (ETFs) ...

    Read more

  • 5 Biotech ETFs If You're Bullish

    06-25-2010 01:00 AM by Tom Lydon

    Biotechnology has helped improve the lives of many people. Naturally, many biotech stocks boom or bust based on the success of products in their pipeline. But if youre looking for a more diversified and steady approach to biotech investing, look no further than exchange traded fu...

    Read more

  • Biotech ETFs: Where the Future Lies

    02-05-2010 02:00 PM by Tom Lydon

    Biotechnology is continuously advancing and the future may lie in personalized medicine. The biotech sector, along with related exchange traded funds (ETFs), may see billions in revenue as this market grows in the coming years. Biotech companies, investors, providers and big p...

    Read more

  • Biotechnology: Why ETFs Suit the Sector

    11-19-2009 02:00 PM by Tom Lydon

    The biotechnology sector is once again finding its footing, with some exchange traded funds (ETFs) focused on the sector up more than 30% since the market's March 9 low. But there have been stumbling blocks on the way back to profitability. A reputable biotechnology company h...

    Read more

  • What Biotechnology ETFs Need to Thrive

    09-04-2009 02:00 PM by Tom Lydon

    The biotechnology sector and its related exchange traded funds (ETFs) have seen a handsome rebound off the March 9 lows, but does the cash-strapped sector have what it takes to survive for the long haul? Analysts estimate that nearly half of all biotechnology firms have insuf...

    Read more

  • 7 Reasons Biotechnology ETFs Could Succeed

    08-06-2009 01:00 AM by Tom Lydon

    The biotechnology sector and exchange traded funds (ETFs) have had a good summer so far. Some funds are up as much as 22% in the last month alone. Will it continue? July was kind to the biotech sector. The NYSE Biotechnology Sector rose up 24%, which dwarfed the 6% for the S&a...

    Read more

  • ETF Spotlight: PowerShares Dynamic Biotech & Genome (PBE)

    07-29-2009 02:00 PM by Tom Lydon

    ETF Spotlight on PowerShares Dynamic Biotech & Genome (PBE), part of a weekly series. Assets: $148 million Holdings: This fund invests in companies involved in the biotechnology and genome sectors. Some of the top components include ImmunoGen (IMGN), Amgen (AMGN), Gilead S...

    Read more

  • Biotech Sector and ETFs Get a Lifeline

    07-08-2009 12:00 PM by Tom Lydon

    A small piece of the 2009 Economic Stimulus Package will revamp aid to small businesses, which could give way to successful relationships between small pharmaceutical/biotech companies andacademic institutions. This may be what related investments and exchange traded funds (ETFs...

    Read more

  • Health Care Reform and Biotech ETFs: Will There Be Opportunities?

    06-27-2009 01:00 AM by Tom Lydon

    In an attempt to reduce costs in the health care industry, the government will be legislating for cheaper drugs, but drug makers, along with related exchange traded funds (ETFs), may see profits slip away. The Obama administration claims that biologic drugs should be subject t...

    Read more

  • Why Biotech ETFs May Be the Better Choice

    06-17-2009 11:00 AM by Tom Lydon

    Biotechnology stocks present opportunities, but given the unique challenges of the sector, exchange traded funds (ETFs) may be the better route to go if you're considering making an investment. Owning individual biotechnology companies can be a challenging way to invest in th...

    Read more

  • Can Obama's Push Reignite Biotech and Health Care ETFs?

    06-15-2009 12:00 PM by Tom Lydon

    Biotechnology and health care-related exchange traded funds (ETFs) could be set to take off as both sectors are in a transition period and are gaining more support from the Obama administration. President Barack Obama today met with the American Medical Association about his ...

    Read more

  • Health Care ETFs' $140 Billion Boost

    02-19-2009 06:00 AM by Tom Lydon

    When President Barack Obama put his John Hancock on the $787 billion stimulus package, $140 billion of it was related specifically to fixing health care and, in turn, related exchange traded funds (ETFs). What's in the bill? A provision to help workers who lose their j...

    Read more

  • PowerShares' ETF Family Grows With Biotech, Commodities

    09-18-2008 12:00 PM by Tom Lydon

    The PowerShares exchange traded fund (ETF) family is adding a slew of new members this week. The PowerShares Global Biotech Portfolio (PBTQ) covers the growth of this industry. The biotech industry has seen increasing growth and revenue base over the past two years. No single ...

    Read more

  • Biotech ETFs Are a Matter of Personal Choice

    07-27-2008 01:00 AM by Tom Lydon

    Biotechnology appeals to many investors, and with four different exchange traded funds (ETFs) focused on the class, is there a fund that is better than the rest? The sector is one of the few non-commodity related that's solidly above its trend line. Each of the four ETFs wi...

    Read more

  • Biotechnology ETFs Growing...Like Genetically Modified Crops?

    07-16-2008 11:00 AM by Tom Lydon

    Biotechnology is the non-commodity exchange traded fund (ETF) area du jour, it seems. In a time where the markets seem bleak, the sector is delivering a ray of light. Genentech (DNA) this week upped its 2008 forecast, and also said its second-quarter profit rose 4.7%, thanks t...

    Read more